Adaptive Biotechnologies Past Earnings Performance
Past criteria checks 0/6
Adaptive Biotechnologies's earnings have been declining at an average annual rate of -23.3%, while the Life Sciences industry saw earnings growing at 16% annually. Revenues have been growing at an average rate of 20.4% per year.
Key information
-23.3%
Earnings growth rate
12.8%
EPS growth rate
Life Sciences Industry Growth | 21.5% |
Revenue growth rate | 20.4% |
Return on equity | -78.3% |
Net Margin | -123.2% |
Last Earnings Update | 31 Mar 2024 |
Recent past performance updates
Recent updates
Is Adaptive Biotechnologies (NASDAQ:ADPT) Using Too Much Debt?
May 08It's Down 26% But Adaptive Biotechnologies Corporation (NASDAQ:ADPT) Could Be Riskier Than It Looks
Apr 03Adaptive Biotechnologies: A Post Earnings Assessment
Feb 25Analysts Just Shaved Their Adaptive Biotechnologies Corporation (NASDAQ:ADPT) Forecasts Dramatically
Feb 17Not Many Are Piling Into Adaptive Biotechnologies Corporation (NASDAQ:ADPT) Stock Yet As It Plummets 25%
Feb 01Analysts Are More Bearish On Adaptive Biotechnologies Corporation (NASDAQ:ADPT) Than They Used To Be
Nov 17Is Adaptive Biotechnologies (NASDAQ:ADPT) A Risky Investment?
Oct 13Is Adaptive Biotechnologies (NASDAQ:ADPT) A Risky Investment?
Jul 06Investors Give Adaptive Biotechnologies Corporation (NASDAQ:ADPT) Shares A 26% Hiding
May 05We're Hopeful That Adaptive Biotechnologies (NASDAQ:ADPT) Will Use Its Cash Wisely
Apr 15Adaptive Biotechnologies (NASDAQ:ADPT) Is In A Good Position To Deliver On Growth Plans
Dec 13Adaptive Biotechnologies, Epic team up to integrate clonoSEQ test in electronic record system
Oct 11Adaptive Biotechnologies announces $250M non-dilutive royalty financing
Sep 12We're Not Very Worried About Adaptive Biotechnologies' (NASDAQ:ADPT) Cash Burn Rate
Aug 14Companies Like Adaptive Biotechnologies (NASDAQ:ADPT) Are In A Position To Invest In Growth
Apr 29Adaptive Biotechnologies: Good Buy For Long-Term Investors
Apr 15Are Investors Undervaluing Adaptive Biotechnologies Corporation (NASDAQ:ADPT) By 22%?
Feb 26We Think Adaptive Biotechnologies (NASDAQ:ADPT) Can Afford To Drive Business Growth
Jan 09Our First Assessment On Adaptive Biotechnologies
Dec 16Adaptive Biotechnologies (NASDAQ:ADPT) Is In A Good Position To Deliver On Growth Plans
Sep 26Revenue & Expenses BreakdownBeta
How Adaptive Biotechnologies makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
31 Mar 24 | 175 | -215 | 171 | 99 |
31 Dec 23 | 170 | -225 | 173 | 102 |
30 Sep 23 | 180 | -196 | 176 | 152 |
30 Jun 23 | 190 | -191 | 178 | 152 |
31 Mar 23 | 184 | -195 | 177 | 152 |
31 Dec 22 | 185 | -200 | 184 | 124 |
30 Sep 22 | 168 | -221 | 188 | 0 |
30 Jun 22 | 160 | -232 | 191 | 0 |
31 Mar 22 | 155 | -229 | 185 | 0 |
31 Dec 21 | 154 | -207 | 170 | 128 |
30 Sep 21 | 147 | -190 | 152 | 0 |
30 Jun 21 | 133 | -171 | 133 | 0 |
31 Mar 21 | 116 | -155 | 121 | 0 |
31 Dec 20 | 98 | -146 | 111 | 0 |
30 Sep 20 | 92 | -122 | 100 | 0 |
30 Jun 20 | 92 | -99 | 91 | 0 |
31 Mar 20 | 93 | -82 | 80 | 0 |
31 Dec 19 | 85 | -70 | 69 | 0 |
30 Sep 19 | 78 | -62 | 63 | 0 |
30 Jun 19 | 69 | -56 | 56 | 0 |
31 Mar 19 | 59 | -53 | 50 | 0 |
31 Dec 18 | 56 | -46 | 45 | 0 |
31 Dec 17 | 38 | -43 | 33 | 0 |
Quality Earnings: ADPT is currently unprofitable.
Growing Profit Margin: ADPT is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: ADPT is unprofitable, and losses have increased over the past 5 years at a rate of 23.3% per year.
Accelerating Growth: Unable to compare ADPT's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: ADPT is unprofitable, making it difficult to compare its past year earnings growth to the Life Sciences industry (-6.6%).
Return on Equity
High ROE: ADPT has a negative Return on Equity (-78.3%), as it is currently unprofitable.